Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia

ClinicalTrials.gov ID: NCT00357825

Public ClinicalTrials.gov record NCT00357825. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study of [S,S]-Reboxetine Administered Once Daily in Patients With Fibromyalgia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety and effectiveness of \[S,S\]-Reboxetine in patients with fibromyalgia.

Study identification

NCT ID
NCT00357825
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
246 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2006
Primary completion
Feb 28, 2007
Completion
Feb 28, 2007
Last update posted
May 14, 2013

2006 – 2007

United States locations

U.S. sites
61
U.S. states
25
U.S. cities
54
Facility City State ZIP Site status
Pfizer Investigational Site Chandler Arizona 85225
Pfizer Investigational Site Phoenix Arizona 85007
Pfizer Investigational Site Phoenix Arizona 85013
Pfizer Investigational Site Sun City Arizona 85351
Pfizer Investigational Site Tucson Arizona 85741
Pfizer Investigational Site Auburn California 95602
Pfizer Investigational Site Orangevale California 95662
Pfizer Investigational Site Pismo Beach California 93449
Pfizer Investigational Site Walnut Creek California 94598
Pfizer Investigational Site Newark Delaware 19713
Pfizer Investigational Site DeLand Florida 32720
Pfizer Investigational Site Ocala Florida 34471
Pfizer Investigational Site Ocala Florida 34474
Pfizer Investigational Site Tampa Florida 33606
Pfizer Investigational Site Tampa Florida 33614
Pfizer Investigational Site West Palm Beach Florida 33407
Pfizer Investigational Site Gurnee Illinois 60031
Pfizer Investigational Site Moline Illinois 61265
Pfizer Investigational Site Indianapolis Indiana 46250
Pfizer Investigational Site Pratt Kansas 67124
Pfizer Investigational Site Lexington Kentucky 40509
Pfizer Investigational Site Fall River Massachusetts 02720
Pfizer Investigational Site Mansfield Massachusetts 02048
Pfizer Investigational Site Wellesley Hills Massachusetts 02481-2106
Pfizer Investigational Site Worcester Massachusetts 01610
Pfizer Investigational Site Jefferson City Missouri 65109
Pfizer Investigational Site Kansas City Missouri 64106
Pfizer Investigational Site St Louis Missouri 63141
Pfizer Investigational Site Lincoln Nebraska 68516
Pfizer Investigational Site New York New York 10022-1009
Pfizer Investigational Site Cary North Carolina 27511
Pfizer Investigational Site Charlotte North Carolina 28209-3734
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Raleigh North Carolina 27609
Pfizer Investigational Site Minot North Dakota 58701
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Cincinnati Ohio 45227
Pfizer Investigational Site Dayton Ohio 45402
Pfizer Investigational Site Toledo Ohio 43623
Pfizer Investigational Site Eugene Oregon 97401
Pfizer Investigational Site Medford Oregon 97504
Pfizer Investigational Site Altoona Pennsylvania 16602
Pfizer Investigational Site Bensalem Pennsylvania 19020
Pfizer Investigational Site Bethlehem Pennsylvania 18015
Pfizer Investigational Site Camp Hill Pennsylvania 17011
Pfizer Investigational Site Duncansville Pennsylvania 16635-0909
Pfizer Investigational Site Cumberland Rhode Island 02864
Pfizer Investigational Site Myrtle Beach South Carolina 29572
Pfizer Investigational Site Milan Tennessee 38358
Pfizer Investigational Site Nashville Tennessee 37203
Pfizer Investigational Site Georgetown Texas 78626
Pfizer Investigational Site Houston Texas 77024
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site Lake Jackson Texas 77566
Pfizer Investigational Site San Antonio Texas 78213
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Salt Lake City Utah 84102
Pfizer Investigational Site Virginia Beach Virginia 23455
Pfizer Investigational Site Everett Washington 98201
Pfizer Investigational Site Tacoma Washington 98405
Pfizer Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Pain trials

Other public records listing Pain. Sorted by last update posted; newest first. Not a recommendation.

All Pain trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00357825, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 14, 2013 · Synced Sep 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00357825 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →